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Spinal Muscular Atrophy (SMA) is a recessive genetic disorder that is characterized by 
selective loss of lower motor neurons and atrophy of muscle.  It is the most common genetic 
cause of infant mortality and is caused by the loss of the SMN1 (Survival Motor Neuron) gene 
and retention of SMN2, which results in low levels of SMN protein.   SMN functions in assembly 
of Sm proteins onto snRNAs and these RNPs function in splicing.  Several mouse models have 
been developed to study the different types of SMA.  Intermediate SMA mice (SMN2 +/+; Smn -
/-; SMNΔ7 +/+) live an average of 14 days and express low levels of SMN protein.  To 
investigate if expressing SMN in neurons would increase survival past 14 days, intermediate 
SMA mice were crossed to mice containing the ChAT-SMN transgene.  ChAT-SMN expresses 
SMN in mature neurons.  The results indicate increased expression of SMN in mature neurons 
does not increase survival of intermediate SMA mice past their normal lifespan. 
Additionally, we are creating a Drosophila model of SMA to study the effect of Smn 
missense mutations on survival.  Drosophila has one Smn gene and loss of Smn protein is lethal 
at the larval stage.  To investigate the effect of missense mutations on survival, we are 
introducing them into a Smn null background to see if survival is increased past the larval lethal 
stage.  Patient mutations SMND44V and G279V (D20V and G210V in Drosophila) were chosen 
due to 100% identity of amino acids between human and fly and the type of SMA they cause in 
humans.  D44V is a mild form of SMA (Type III) while G279V causes a severe form of SMA 
(Type I).  Site-directed mutagenesis was performed to introduce the missense mutations into 
Drosophila Smn and the gene was subcloned into the pUAST vector.  The plasmid will be 
injected in Drosophila embryos and the resulting flies crossed into the Smn null background.  
Three additional mutations, V94G, G95R, and Y130C (V72G, G73R, Y107C in Drosophila), 
were selected to study their effect on survival as well.  Site-directed mutagenesis was performed 
on Drosophila Smn and the constructs remain to be subcloned and sequenced.   Based on the 
results of these experiments, biochemical assays will be performed to determine the level of 
snRNP assembly in surviving flies to see if there is a relationship between levels of snRNP 
assembly and the type of SMA.  Additionally, mutations that extend the flies past the larval stage 






Spinal Muscular Atrophy (SMA) is an autosomal recessive disorder that is characterized 
by selective loss of lower motor neurons and atrophy of muscle (1).  It is the most common 
genetic cause of infant mortality in humans (2). SMA is caused by loss of the telomeric survival 
motor neuron (SMN1) gene and retention of the centromeric SMN2 gene (3,4).  Loss of both 
SMN genes is embryonic lethal (4,7,8).  SMN1 and SMN2 are 99.9% identical and the critical 
difference between the two genes is a C-T change in exon 7 of SMN2, which does not alter the 
encoded amino acids but does alter the amount of exon 7 incorporated in the final SMN 
transcript (3,9,10,11,12,13).  The SMN1 gene produces full-length transcripts whereas the 
majority of the SMN2 transcripts lack exon 7(3, 13).  The lack of exon 7 leads to an unstable 
protein that is unable to oligomerize efficiently and is rapidly degraded (14,15).  As a result, a 
single SMN2 gene produces considerably less SMN protein than a SMN1 gene (5,6).  Thus the 
disease is caused, not by lack of SMN protein, but by low levels of SMN protein (5,6).   
The severity of SMA can be divided into three groups based on clinical presentation.  
Type I SMA is the most severe form of SMA with onset before 6 months and death occurring by 
the age of 2 years (1).  Type II SMA is intermediate in severity with onset before 18 months of 
age and patients never gaining the ability to walk (1).  Type III SMA is the mildest form of the 
disease with onset after 18 months and retains the ability to walk (1). 
The most well characterized function of SMN is in snRNP (small nuclear ribonucleic 
protein) assembly (16,17,18,19).  SnRNPs contain small nuclear RNA in a specific protein 
complex (16,20).  The SMN protein assembles Sm protein onto snRNA (16,17,18).  SnRNPs in 
the nucleus are important for the splicing of genes (16).  SnRNP assembly is essential for cell 
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survival (16), however, it is unclear if disruption of snRNP assembly is the cause of SMA.  In 
addition to its role in assembly of snRNPs, SMN also associates with numerous other proteins 
(16,21,22). SMN has been found in the axons and growth cones of neurons (23, 24, 25, 26).  In 
contrast to the motor neuron cell body, antibody staining in motor  axons appears to indicate that 
the vast majority of SMN is not complexed to a known snRNP component, Gemin2 (27).  This 
has led to competing hypotheses of whether the function of SMN that is disrupted in SMA is 
involved in splicing or if there is another unknown SMN complex in axons that leads to the 
motor neuron disorder.  
The SMN gene is highly conserved among different species, including Drosophila and 
mouse (28, 38).  In both species there is one survival motor neuron (Smn) gene that is equivalent 
to SMN1 (28,36,38).  Complete loss of this gene results in early embryonic lethality in mice (39) 
and larval lethality in Drosophila (40), as would be expected given SMN’s critical role in snRNP 
assembly (18). 
Drosophila Models of SMA 
 Five percent of SMA cases have small mutations including missense mutations in SMN1.  
Severity of the mutation corresponds to the type of SMA the patient has while also taking into 
account the SMN2 copy number, which has been shown to modulate the phenotype with 
increasing copies of SMN2 (30).  Several SMA patient mutations occur in amino acids that are 
conserved between fly and human.  Figure 1 shows the alignment of human, mouse, Zebrafish, 
and Drosophila SMN along with reported SMA patient missense mutations.  Two Drosophila 




(G202S and S201F) have been reported that disrupt 
oligomerization and are equivalent to the severe Y272C mutation in humans (28,32).  These 
mutations are effectively null alleles for Smn function. Homozygous Smn
73Ao 
mutants are larval 
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lethal and embryonic lethal in the absence of maternal Smn (40).  The restoration of Smn 
expression in all tissues is required to rescue larval lethality and ubiquitous expression of UAS-
Smn using the GAL4 system does rescue the larval lethality (40).  Table 1 shows five of the 
conserved mutations that were used in this experiment. 
 
Figure 1. Alignment of SMN. The blue letters indicate patient missense mutations, red 
highlights the identical amino acids. (Mut) mutation, (Hum) Human, (Mo) Mouse, (Zfish) 





Mouse Models of SMA 
 Several mouse models have been developed to investigate SMN function in SMA.  The 
embryonic lethal phenotype caused by complete loss of the mouse Smn gene is rescued by the 
introduction of two copies of SMN2, resulting in mice with severe SMA that live an average of 5 
 







SMN2 Copy  # 
 
Fly Mutation  
in Smn 
D44V  2a  3 1  D20  
V94G  3  2 3  V72  
G95R  3  3 1  G73  
Y130C  3  3 2  Y107  
G279V  7  1 ND   G210  




days, whereas eight copies of SMN2 allows the mice to live normal lifespans (30).  SMN2 
produces the required functional SMN protein for cells to survive.  An intermediate SMA mouse 
model has also been developed that is representative of type II SMA.  While SMN2 produces 
some full-length SMN, the majority of the transcripts generated from SMN2 lack exon 7 (3, 13).  
In the intermediate SMA model, a transgene was constructed that placed an SMN cDNA lacking 
exon 7 (SMNΔ7) under the control of the SMN promoter.  The SMNΔ7 mice were then crossed 
onto the severe SMA background.  Expression of SMN Δ7 modulates the severe SMA phenotype 




Site-Directed Mutagenesis. Five SMA patient missense mutations that occur in amino acids of 
100% identity between human SMN1 and Drosophila Smn were chosen for site-directed 
mutagenesis.  The mutations chosen were D44V, V94G, G95R, Y130C, and G279V (D20, V72, 
G73, Y107, and G210 in fly).  These mutations, shown in Table 1, are of varying severities due 
to the type of SMA they cause and the number of copies of SMN2.   D44V and G95R are mild 
mutations (33, 34), V94G and Y130C (35, 37) are intermediate mutations, and G279V (41) 
corresponds to a severe mutation.  To investigate the effect of missense mutations on survival, 
we are introducing them into the Smn
73Ao
 null background to see if survival is increased past the 
larval lethal stage.  All five missense mutations have been introduced to Drosophila Smn in the 
pOT2 vector using site-directed mutagenesis.   
 To screen for clones containing the desired mutations, a series of diagnostic digests were 
utilized.  Potential clones were digested with EcoRI and XhoI to confirm the presence of the 
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841bp Smn insert.  Digests specific for each mutation were set up to detect the presence of the 
mutation in the different clones.  For D20, a new PshAI site was created by the mutation.  
Potential clones were double digested with PshAI and XhoI and the presence of an extra band 
compared to wild type Smn/pOT2 indicated the mutation was present.  Because the mutation was 
localized close to the 5′ end of Smn, the PshAI and XhoI digest essentially excised the insert 
whereas wild type Smn was only linearized.  Potential G210 clones were digested with EcoRI 
and BsaJI.  The G210 mutation causes Smn to lose a BsaJI site and positive clones were 
identified by the absence of a band as compared to wild type fly Smn.  Five D20 mutations and 
one G210 mutation were identified and confirmed through sequencing. 
 Mutations V72 and G73 also utilized digests to identify potential positive clones but used 
a different screening approach due to the complicated banding pattern that resulted from 
digesting the entire plasmid.  To identify clones containing these mutations, the Smn insert only 
was amplified using a primer in the pOT2 vector just outside the 5′ end of the gene and an 
internal primer at the 3′ end.  After confirming the presence of Drosophila Smn by a positive 
band after running out an aliquot of PCR reaction on a 1.2% agarose gel, diagnostic digests were 
set up on the remaining PCR product to identify positive clones.  V72 gains a new MnlI site and 
G73 gains a new RsaI site.  As many small fragments resulted from this digest, the product was 
run out on a MetaPhor Agarose high resolution gel and compared to the wild type Smn pattern to 
identify clones.  The Y107 mutation did not result in any changes in the restriction enzyme sites 
and will have to be identified through sequencing.  All three mutations remain to be sequenced to 
confirm positive clones. 
Subcloning into pUAST vector.  The 9056bp pUAST vector contains 3′ and 5′ P-elements, 
UAS sequences, and a white
+
 marker for eye color. These features allow a method of introducing 
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our clone to the Drosophila genome through P-element transformation, a method to express the 
construct using the GAL4 system, and a marker to identify transformants.  The 841bp Smn gene 
containing either the D20 or G210 mutation as well as wild type Smn was excised from the pOT2 
vector using EcoRI and XhoI.  The pUAST vector was digested with same enzymes and then 
dephosphorylated to ensure that in future ligation steps the vector would not close on itself 
without the insertion of the Smn gene.  Both sets of digests were run out on a 0.7% gel to 
separate the fragments.  The bands corresponding to approximately 850 kb in the fly Smn/pOT2 
digest and 9 kb in the pUAST digest were removed from the gel and gel purified to obtain the 
DNA.  The presence of different sticky ends from EcoRI and XhoI in the linearized pUAST 
vector and Smn allowed for ligation in the correct orientation of the two fragments and 
recircularization of the plasmid.   
 Positive clones were identified using the same method as in the pOT2 vector.  Potential 
positive clones were screened by first digesting with EcoRI and XhoI to confirm the presence of 
the insert and then digesting with the mutations’ respective diagnostic restriction enzymes.  
Positive clones were identified by comparing the banding pattern of the mutated fly Smn/pUAST 
with wild type and detecting differences.  D20/pUAST gains a new PshAI site and the existence 
of a band at approximately 850 kb after a XhoI and PshAI double digest indicated the presence 
of the mutation.  G210/pUAST potential clones were digested with EcoRI and BsaJI and resulted 
in many different fragment lengths.  The banding pattern was compared with wild type and the 
presence of a new band at approximately 750 bp identified the mutants.  The positive clones 
were sequenced to confirm the mutation was present and the gene remained intact.  V72, G73, 
and Y107 still remain to be subcloned in the pUAST vector. 
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Germline transformation in Drosophila. P-element transformation was used to introduce the 
mutated and wild type Drosophila Smn/pUAST construct into Drosophila embryos.  The pUAST 
vector contains a 5′ and 3′ P-element flanking the Smn gene and several other necessary 
sequences such as a marker for eye color and UAS binding sequences.  P-elements are 
transposable elements that are able to randomly insert themselves into genomic DNA.  The 
pUAST vector contains P-elements engineered without a transposase gene regulating DNA 
insertion.  Defective P-elements require trans-acting transposase of the intact element for 
transposition.  This transposase is provided by a helper plasmid that is co-injected with the 
construct of interest.  The Smn/pUAST constructs were co-injected with Δ2-3 transposase, a P-
element that is active in supplying transposase but due to a deletion of exons 2 and 3 is unable to 
transpose itself.  This allows only the P-elements within the pUAST vector to be randomly 
inserted into the Drosophila germline.  The construct was injected into embryos before the 
formation of the pole cells so that a stable, transmissible germline was created.   
 The P-element containing the Smn gene contained a white
+ 
marker that allowed 
identification of transformants by the presence of orange or red eyes in the w
-
 fly stocks.  All 
crossing and maintenance of fly stocks was done by Dr. McGovern. 
 Expression of the mutated Smn genes will occur through the GAL4 system.  The GAL4 
system allows for directed gene expression in Drosophila.  The Smn gene was subcloned behind 
GAL4 binding sites and is silent in the absence of GAL4.  Flies carrying UAS-Smn will be 
crossed to flies expressing GAL4 and the trans-acting protein will activate the gene to produce 
mutant protein.  Our transformants will be crossed to flies expressing GAL4 under the tubulin 
promoter to allow for ubiquitous expression of UAS-Smn in the flies.  The flies will then be 
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assessed for survival to determine if the mutations extend the lifespan of the flies past larval 
lethality. 
Aim 2 
Mouse Breeding.  An intermediate SMA mouse model (SMN2 +/+; Smn -/-; SMNΔ7 +/+) was 
previously developed by Le, et al (2005).  These Δ7 mice live an average of 14 days and express 
SMNΔ7 protein and low levels of full length SMN protein.  To investigate if increased 
expression of SMN in mature neurons or muscle would extend survival past 14 days, 
intermediate SMA mice (SMN2 +/+; Smn +/-; SMNΔ7 +/+) were crossed to mice containing the 
ChAT-SMN transgene (SMN2 +/+; Smn +/-; ChAT-SMN) or HSA-SMN transgene (SMN2 
+/+; Smn +/-; HSA-SMN).    ChAT-SMN expresses high levels of SMN in mature motor 
neurons under the choline acetyltransferase promoter beginning at postnatal day 5 (PND05) (44).  
HSA-SMN expresses high levels of SMN under the human skeletal actin promoter in muscle 
tissue only (42).  Table 2 summarizes the results.  A total of 10 intermediate SMA animals 
positive for ChAT-SMN were produced and had a mean survival of 13.9 days.  One intermediate 
SMA mouse with HSA-SMN resulted from the crosses and lived for 12.5 days.  Intermediate 
SMA mice crossed to both ChAT-SMN and HSA-SMN resulted in three progeny that survived 
an average of 16.8 days.  Overall, the 14 intermediate SMA mice that resulted from these crosses 
lived an average of 14.4 days. 




Intermediate SMA mice  Ref. 1  14  
Intermediate SMA mice + ChAT-SMN  10  13.9  
Intermediate SMA mice + HSA-SMN  1  12.5  
Intermediate SMA mice + ChAT-SMN+ HSA-SMN  3  16.8  
Total Animals 14  14.4  
Table 2. Summary of mouse genotypes and survival 
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 Increased expression of SMN in mature neurons under the ChAT promoter or in muscle 
only under the human skeletal actin promoter does not appear to rescue intermediate SMA mice.  
Neither transgene was able to significantly extend survival of the SMNΔ7 mice past the normal 
14 days by itself or in combination with each other.   
DISCUSSION 
Aim 1.  The five SMN missense mutations introduced in to Drosophila Smn were chosen because 
they occur in amino acids of 100% identity between the two species and for the severity of the 
mutation in humans.  The flies will be crossed onto a Smn null background and survival will be 
assessed to see if the mutant protein allows the flies to live past the larval lethal stage.   
 I would predict the milder SMN mutations allow for survival.  While it is unknown what 
role of SMN is affected in SMA, it could be either snRNP assembly or another unknown 
function specific to motor neurons.  The milder mutations like D44V and G95R are predicted to 
result in the least disruption of SMN’s function in SMA. 
Flies that survive past the larval stage will be used for snRNP assays to measure the level 
of snRNP assembly that can help determine if there is a correlation between disruption of snRNP 
assembly and the severity of SMA.  If snRNP assembly is the SMN complex implicated in SMA, 
it would be expected that severe SMN mutations would have the greatest reduction in snRNP 
levels and milder SMN mutations would have a mildly reduced disruption of snRNP assembly.  
The results from snRNP assays will help researchers to move closer to identifying the role of 
SMN that is disrupted in motor neurons and leads to SMA.  If a mutation rescues flies then the 
mutation will be introduced into mice to generate a mammalian model of SMA.  While 
Drosophila is a powerful genetic model that allows a fast and easy way to screen the mutations, a 




Aim 2.  Expressing increased levels of SMN in mature neurons or muscle did not increase 
survival of intermediate SMA mice past the normal 14 day lifespan.  Furthermore, increased 
expression of SMN in muscle tissue in addition to increased expression in mature neurons did 
not result in rescue of the animals either.    
 In a recently published study, severe SMA mice were rescued by the increased expression 
of SMN in neurons during embryonic development whereas expression of SMN in muscle only 
was insufficient to rescue these mice.  Severe SMA mice live an average of 5 days (30).  Full-
length SMN was expressed under the Prion promoter (PrP) and reached high levels in neurons at 
embryonic day 15 (50).  These mice survived an average of 297 days, with expression of PrP-
SMN resulting in complete rescue (42).  Expression of HSA-SMN in muscle resulted in no 
extension of survival (42).  The authors concluded that high expression of full-length SMN in 
neurons can correct the severe SMA phenotype in mice, while high SMN levels in muscle alone 
has no impact. 
 ChAT-SMN was also previously shown not to rescue severe SMA mice.  While PrP-
SMN expression is high embryonically, high expression of ChAT-SMN occurs later at PND05. 
This coincides with the time of death of the SMA animals.  In this model it is likely that the 
increased expression of SMN was occurring too late to rescue the severe SMA mice.  Since 
intermediate SMA mice live an average of 14 days, it was plausible that ChAT-SMN expression 
could rescue these mice.  The results indicate that ChAT-SMN either does not express SMN 
early enough or not at a high enough level to rescue intermediate SMA mice or it needs to be 
expressed in more than just motor neurons. 
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 These results taken in context with the study expressing PrP-SMN and HSA-SMN in 
severe SMA mice indicate timing and levels of expression is important for rescue and high SMN 
expression needs to take place at least before PND05 in severe and intermediate SMA mice.  The 
results also indicate that high expression of SMN in muscle alone is not sufficient to rescue 
severe or intermediate SMA mice.  SMN expression in muscle in addition to SMN expression in 
mature neurons in intermediate SMA mice also is not sufficient to rescue.  This suggests that 
earlier expression of SMN in motor neurons or additional neural subtypes is required for rescue 
of intermediate SMA mice. 
 
MATERIALS AND METHODS 
Site-Directed Mutagenesis.  Drosophila Smn cDNA (clone LD36939) was obtained from the 
Drosophila Genomic Resource Center.  The 841bp Smn fragment was previously cloned into the 
pOT2 vector between EcoRI and XhoI.  SMA missense mutations D44V, V94G, G95R, Y130C, 
and G279V (D20V, V72G, V73G, Y107C, and G210V in Drosophila) were selected for site-
directed mutagenesis.  Stratagene QuikChange Site-Directed Mutagenesis Kit protocol was 
followed.  The PCR was conducted in a 50 l reaction with 5 l 10x PfuTurbo reaction buffer, 
50 ng dsDNA template, 125 ng forward and reverse oligonucleotide primers, 1 l 10 mM 
dNTPs, and 1 l PfuTurbo DNA polymerase (2.5 l, Stratagene).  The PCR primers for D20V 
were 5′-GGTGAAGACGTACGTCGAGTCGGTGGGAC-3′ and 5′-
GTCCCACCGACTCGACGTACGTCTTCACC-3 , for V72G were 5′-
CAGTATCCTTCAAAGGAGGCGGCGACTACGCCAG-3′ and 5′-




CCCTGGCGTAGTCGCGTACTTTGAAGGATAC-3′, for Y107C were 5′-
CTCCGCTATTTGGGCTGTGAGAACGAGCAGGAG-3′ and 5′-
CTCCTGCTCGTTCTCACAGCCCAAATAGCGGAG-3′, and for G210V were 5′-
CGGGCCTCTACCAGGTAAAGAAAGAAGCCAG-3′ and 5′-
CTGGCTTCTTTCTTTACCTGGTAGAGGCCCG-3′.  PCR reaction conditions are as follows: 
95  for 2 minutes; 12 cycles of 95  for 30 seconds and 68  for 11 minutes.  The methylated, 
non-mutated parental strand was digested with 2 l DpnI (Invitrogen) for one hour at 37 .  The 
DpnI digested product was transformed into XL1 Blue supercompetent cells (Stratagene) 
according to the manufacturer’s protocol and grown on LB and chloramphenicol plates to screen 
for potential mutants.   
Subcloning into pUAST vector.  Drosophila Smn in the pOT2 vector and a separate sample of 
the pUAST vector were digested in a 40 l reaction with EcoRI and XhoI and run out on a 0.7% 
agarose gel to separate the fragments.  The 841 bp fragment corresponding to Smn and an 
approximately 9 kb fragment corresponding to the pUAST vector were excised and gel purified 
using the QIAquick Gel Extraction kit (Qiagen #28706).  The Smn fragment and linearized 
vector were then ligated using DNA ligase.  The ligation product was transformed into DH5α 
cells and plated on LB and ampicillin plates.  DNA was purified using a phenol/chloroform 
extraction.  Possible positive clones were screened by digestion with (1) EcoRI and XhoI to 
determine if they contained the insert and (2) PshAI and XhoI for D20, BsaJI and EcoRI for 
G210, MnlI for V72 and RsaI for G73.  Clones were also screened through whole colony PCR 
using the primers T7 5′- TAATACGACTCACTATAGGG -3′ and flySmn1R 5′-
GATGGAATTACTTCTTGGGTGTC-3′ to amplify the Smn insert in the pOT2 vecor and 
pUAST 1F 5’-CAAAGTGAACACGTCGCTAAGC-3’ and flySmn1R 5′-
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GATGGAATTACTTCTTGGGTGTC-3′ to determine the presence of the Smn insert in the 
pUAST vector.  The reaction conditions were as follows: 95  for 5 min; 30 cycles of 95  for 1 
min, 59  for 1 min, 72  for 1 min; 72  for 5 min.   
The PCR product of potential clones containing the insert was then digested with the restriction 
enzyme indicated above as a diagnostic for the mutation.  DNA was purified using the QIAprep 
Spin Miniprep kit (Qiagen #27106) and positive clones were confirmed through sequencing at 
the Plant-Microbe Genomics Facility at The Ohio State University.   
Germline transformation in Drosophila.  Injection DNA of sequenced clones was obtained by 
using the QIAGEN Plasmid Midi Kit (Qiagen #12143).  Collection chambers with w
-
 fruitflies 
were set up several days in advance by Dr. McGovern.  Embryo collections were taken the day 
of injections on an hourly basis.  Embryos were dechorionated with 50% bleach for 2 minutes 
and rinsed with water.  Embryos were aligned on an apple juice plate slice horizontally with the 
micropyle facing the left and transferred to a strip of tape.  The embryos were desiccated for 3 
minutes and 30 seconds on drying pellets in a large petri dish and then covered with a mixture of 
90% 700 Halocarbon oil, 10% 95 Halocarbon oil (Sigma).  DNA containing Smn in the pUAST 
vector was co-injected with Δ2-3 transposase and buffer by Dr. McGovern.  Transformants were 
identified by crossing to w
-
flies and detecting the presence of orange to red eyes in the next 
generation. 
Mouse genotyping.  PCR reactions were set up to determine the presence or absence of mouse 
Smn, mouse knockout, SMN2, HSA-SMN, ChAT-SMN, Δ7, and PrP-SMN depending on the 
genotypes of the parents.  The primers used to detect mouse Smn were mSMNex2AF 5′-
TTTTCTCCCTCTTCAGAGTGAT-3′ and mSMNex2BR 5′-
CTGTTTCAAGGGAGTTGTGGC-3′.  The mouse knockout allele was genotyped with primers 
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mSMNex2AF 5′-TTTTCTCCCTCTTCAGAGTGAT-3′ and Bgal3R 5′-
GAGTAACAACCCGTCGGATTC-3′.  SMN2 copy number was confirmed using primers that 
flank the insertion site of the SMN2 transgene.  The primers are as follows: Tg89F 5′-
CTGACCTACAGGGATGAGG-3′,  Tg89Grm7negativeR 5′-
CCCAGGTGGTTTATAGACTCAGA-3′, and Tg89SMNpositiveR 5′-
GGTCTGTTCTACAGCCACAGC-3′.  HSA-SMN was detected with the primer HSA 5F 5′-
GAGCCGAGAGTAGCAGTTGT-3′ and a SMN exon 1-2 junction primer 1.2R 5′-
AGAATCATCGCTCTGGCCTGTGCC-3′.   ChAT-SMN was genotyped using the primer 
Chat5F 5′-CTGGATTAAGAATCGCTAGG-3′ and an exon 3 primer 2.3R 5′-
AGTAGATCGGACACAGATTTTGCT-3′.  The primers used to genotype Δ7 were SMNproF 
5′-TGGAGTTCGAGACGAGGCCTAAGC-3′ and 2.3R 5′-
AGTAGATCGGACACAGATTTTGCT-3′.  Prp-SMN was detected using the primers Prion ex2 
F 5′-GGACTCGTGAGTATATTTCAG-3′ and the SMN exon 1-2 junction primer 1.2R 5′-
AGAATCATCGCTCTGGCCTGTGCC-3′.  The thermal cycling conditions for mouse Smn and 
mouse knockout allele PCR reactions are 95  for 3 min; 35 cycles of 95  for 1 min, 57  for 1 
min, 72  for 1 min; 72  for 5 min.  The thermal cycling conditions for SMN2 PCR reaction are 
94  for 3 min; 30 cycles of 94  for 1 min, 63  for 1 min, 72  for 1 min; 72  for 10 min.  
The thermal cycling conditions for HSA-SMN, ChAT-SMN, Δ7, and Prp-SMN PCR reactions 









I would like to thank Dr. Burghes and Dr. McGovern for their incredible patience and assistance 
in advising me on this project.  I would also like to thank Dr. Simcox and Dr. Kolb for being a 
part of my thesis committee. Funding was provided by a College of Arts and Sciences 
Undergraduate Research Scholarship and Mayers Summer Internship so a special thanks to them 






1. Crawford, T.O. and Pardo, C.A. (1996) The neurobiology of childhood spinal muscular 
atrophy. Neurobiol Dis, 3, 97-110. 
2. Roberts, D.F., Chavez, J. and Court, S.D. (1970) The genetic component in child 
mortality. Arch Dis Child, 45, 33-8. 
3. Lefebvre, S., Burglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, 
B., Cruaud, C., Millasseau, P., Zeviani, M. et al. (1995) Identification and 
characterization of a spinal muscular atrophy-determining gene. Cell, 80, 155-65. 
4. Burghes, A.H. (1997) When is a deletion not a deletion? When it is converted. Am J Hum 
Genet, 61, 9-15. 
5. Lefebvre, S., Burlet, P., Liu, Q., Bertrandy, S., Clermont, O., Munnich, A., Dreyfuss, G. 
and Melki, J. (1997) Correlation between severity and SMN protein level in spinal 
muscular atrophy. Nat Genet, 16, 265-9. 
6. Coovert, D.D., Le, T.T., McAndrew, P.E., Strasswimmer, J., Crawford, T.O., Mendell, 
J.R., Coulson, S.E., Androphy, E.J., Prior, T.W. and Burghes, A.H. (1997) The survival 
motor neuron protein in spinal muscular atrophy. Hum Mol Genet, 6, 1205-14. 
7. Hahnen, E., Forkert, R., Marke, C., Rudnik-Schoneborn, S., Schonling, J., Zerres, K. and 
Wirth, B. (1995) Molecular analysis of candidate genes on chromosome 5q13 in 
autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the 
SMN gene in unaffected individuals. Hum Mol Genet, 4, 1927-33. 
8. Schrank, B., Gotz, R., Gunnersen, J.M., Ure, J.M., Toyka, K.V., Smith, A.G. and 
Sendtner, M. (1997) Inactivation of the survival motor neuron gene, a candidate gene for 
human spinal muscular atrophy, leads to massive cell death in early mouse embryos. 
Proc Natl Acad Sci U S A, 94, 9920-5. 
9. Monani, U.R., McPherson, J.D. and Burghes, A.H. (1999) Promoter analysis of the 
human centromeric and telomeric survival motor neuron genes (SMNC and SMNT). 
Biochim Biophys Acta, 1445, 330-6. 
10. Lorson, C.L., Hahnen, E., Androphy, E.J. and Wirth, B. (1999) A single nucleotide in the 
SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl 
Acad Sci U S A, 96, 6307-11. 
11. Cartegni, L. and Krainer, A.R. (2002) Disruption of an SF2/ASF-dependent exonic 
splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat 
Genet, 30, 377-84. 
12. Kashima, T. and Manley, J.L. (2003) A negative element in SMN2 exon 7 inhibits 
splicing in spinal muscular atrophy. Nat Genet, 34, 460-3. 
19 
 
13. Gennarelli, M., Lucarelli, M., Capon, F., Pizzuti, A., Merlini, L., Angelini, C., Novelli, 
G. and Dallapiccola, B. (1995) Survival motor neuron gene transcript analysis in muscles 
from spinal muscular atrophy patients. Biochem Biophys Res Commun, 213, 342-8. 
14. Lorson, C.L., Strasswimmer, J., Yao, J.M., Baleja, J.D., Hahnen, E., Wirth, B., Le, T., 
Burghes, A.H. and Androphy, E.J. (1998) SMN oligomerization defect correlates with 
spinal muscular atrophy severity. Nat Genet, 19, 63-6. 
15. Lorson, C.L. and Androphy, E.J. (2000) An exonic enhancer is required for inclusion of 
an essential exon in the SMA-determining gene SMN. Hum Mol Genet, 9, 259-65. 
16. Eggert, C., Chari, A., Laggerbauer, B. and Fischer, U. (2006) Spinal muscular atrophy: 
the RNP connection. Trends Mol Med, 12, 113-21. 
17. Gubitz, A.K., Feng, W. and Dreyfuss, G. (2004) The SMN complex. Exp Cell Res, 296, 
51-6. 
18. Pellizzoni, L., Yong, J. and Dreyfuss, G. (2002) Essential role for the SMN complex in 
the specificity of snRNP assembly. Science, 298, 1775-9. 
19. Meister, G., Buhler, D., Laggerbauer, B., Zobawa, M., Lottspeich, F. and Fischer, U. 
(2000) Characterization of a nuclear 20S complex containing the survival of motor 
neurons (SMN) protein and a specific subset of spliceosomal Sm proteins. Hum Mol 
Genet, 9, 1977-86. 
20. Will, C.L., Schneider, C., MacMillan, A.M., Katopodis, N.F., Neubauer, G., Wilm, M., 
Luhrmann, R. and Query, C.C. (2001) A novel U2 and U11/U12 snRNP protein that 
associates with the pre-mRNA branch site. Embo J, 20, 4536-46. 
21. Cheng, D., Cote, J., Shaaban, S. and Bedford, M.T. (2007) The arginine 
methyltransferase CARM1 regulates the coupling of transcription and mRNA processing. 
Mol Cell, 25, 71-83. 
22. Claus, P., Bruns, A.F. and Grothe, C. (2004) Fibroblast growth factor-2(23) binds directly 
to the survival of motoneuron protein and is associated with small nuclear RNAs. 
Biochem J, 384, 559-65. 
23. Fan, L. and Simard, L.R. (2002) Survival motor neuron (SMN) protein: role in neurite 
outgrowth and neuromuscular maturation during neuronal differentiation and 
development. Hum Mol Genet, 11, 1605-14. 
24. Sharma, A., Lambrechts, A., Hao le, T., Le, T.T., Sewry, C.A., Ampe, C., Burghes, A.H. 
and Morris, G.E. (2005) A role for complexes of survival of motor neurons (SMN) 
protein with gemins and profilin in neurite-like cytoplasmic extensions of cultured nerve 
cells. Exp Cell Res, 309, 185-97. 
25. Rossoll, W., Kroning, A.K., Ohndorf, U.M., Steegborn, C., Jablonka, S. and Sendtner, M. 
(2002) Specific interaction of Smn, the spinal muscular atrophy determining gene 
20 
 
product, with hnRNP-R and gry-rbp/hnRNP-Q: a role for Smn in RNA processing in 
motor axons? Hum Mol Genet, 11, 93-105. 
26. Zhang, H.L., Pan, F., Hong, D., Shenoy, S.M., Singer, R.H. and Bassell, G.J. (2003) 
Active transport of the survival motor neuron protein and the role of exon-7 in 
cytoplasmic localization. J Neurosci, 23, 6627-37. 
27. Zhang, H., Xing, L., Rossoll, W., Wichterle, H., Singer, R.H. and Bassell, G.J. (2006) 
Multiprotein complexes of the survival of motor neuron protein SMN with Gemins traffic 
to neuronal processes and growth cones of motor neurons. J Neurosci, 26, 8622-32. 
28. Miguel-Aliaga, I., Chan, Y.B., Davies, K.E. and van den Heuvel, M. (2000) Disruption of 
SMN function by ectopic expression of the human SMN gene in Drosophila. FEBS Lett, 
486, 99-102. 
29. Burghes, A.H.M. (2007) RO1 grant submitted to NIH March 5, 2007. The survival motor 
neuron genes in spinal muscular atrophy. 
30. Monani, U.R., Sendtner, M., Coovert, D.D., Parsons, D.W., Andreassi, C., Le, T.T., 
Jablonka, S., Schrank, B., Rossol, W., Prior, T.W. et al. (2000) The human centromeric 
survival motor neuron gene (SMN2) rescues embryonic lethality in Smn (-/-) mice and 
results in a mouse with spinal muscular atrophy. Hum Mol Genet, 9, 333-9. 
 
31. Pellizzoni, L., Charroux, B. and Dreyfuss, G. (1999) SMN mutants of spinal muscular 
atrophy patients are defective in binding to snRNP proteins. Proc Natl Acad Sci U S A, 
96, 11167-72. 
32. Chan, Y.B., Miguel-Aliaga, I., Franks, C., Thomas, N., Trulzsch, B., Sattelle, D.B., 
Davies, K.E. and van den Heuvel, M. (2003) Neuromuscular defects in a Drosophila 
survival motor neuron gene mutant. Hum Mol Genet, 12, 1367-76. 
33. Ogawa, C., Usui, K., Aoki, M., Ito, F., Itoh, M., Kai, C., Kanamori-Katayama, M., 
Hayashizaki, Y. and Suzuki, H. (2007) Gemin2 plays an important role for stabilization 
of the SMN complex. J Biol Chem. 
34. Sun, Y., Grimmler, M., Schwarzer, V., Schoenen, F., Fischer, U. and Wirth, B. (2005) 
Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal 
muscular atrophy. Hum Mutat, 25, 64-71. 
35. Clermont, O., Burlet, P., Benit, P., Chanterau, D., Saugier-Veber, P., Munnich, A. and 
Cusin, V. (2004) Molecular analysis of SMA patients without homozygous SMN1 
deletions using a new strategy for identification of SMN1 subtle mutations. Hum Mutat, 
24, 417-27. 
36. Viollet, L., Bertrandy, S., Bueno Brunialti, A.L., Lefebvre, S., Burlet, P., Clermont, O., 
Cruaud, C., Guenet, J.L., Munnich, A. and Melki, J. (1997) cDNA isolation, expression, 





37. Mihal, D.C., Bridgeman, S.J., Pyatt, R.E. and Prior, T.W. (2007) Sequence analysis of 
small SMN1 mutations in SMA compound heterozygotes. Abstract #1165/C  Presented at 
the annual meeting of The American Society of Human Genetics, October 9-13, 2006, 
New Orleans, Louisiana. Available from  
http://www.ashg.org/genetics/ashg06s/index.shtml. 
38. DiDonato, C.J., Chen, X.N., Noya, D., Korenberg, J.R., Nadeau, J.H. and Simard, L.R. 
(1997) Cloning, characterization, and copy number of the murine survival motor neuron 
gene: homolog of the spinal muscular atrophy-determining gene. Genome Res, 7, 339-
52.S 
 
39. Schrank, B., Gotz, R., Gunnersen, J.M., Ure, J.M., Toyka, K.V., Smith, A.G. and 
Sendtner, M. (1997) Inactivation of the survival motor neuron gene, a candidate gene for 
human spinal muscular atrophy, leads to massive cell death in early mouse embryos. 
Proc Natl Acad Sci USA, 94, 9920-5. 
 
40. Chan, Y.B., Miguel-Aliaga, I., Franks, C., Thomas, N., Trulzsch, B., Sattelle, D., Davies, 
K. and van den Heuvel, M. (2003) Neuromuscular defects in a Drosophila survival motor 
neuron gene mutant. Hum. Mol. Genet. 12(12), 1367-1376. 
 
41. Talbot, K., Ponting, C.P., Theodosiou, A.M., Rodrigues, N.R., Surtees, R., Mountford, R. 
and Davies, K.E. (1997) Missense mutation clustering in the survival motor neuron gene: 
a role for a conserved tyrosine and glycine rich region of the protein in RNA 
metabolism? Hum Mol Genet, 6, 497-500. 
42. Gavrilina, T.O., et al. (2008) Neuronal SMN expression corrects spinal muscular atrophy 
in severe SMA mice while muscle-specific SMN expression has no phenotypic effect. 
Hum. Mol. Genet. 17(8), 1063-1075. 
 
43. Le, T.T., Pham, L.T., Butchbach, M.E., Zhang, H.L., Monani, U.R., Coovert, D.D., 
Gavrilina, T.O., Xing, L., Bassell, G.J. and Burghes, A.H. (2005) SMNDelta7, the major 
product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice 
with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet, 14, 
845-57. 
44. Naciff, J.M., Behbehani, M.M., Misawa, H. and Dedman, J.R. (1999) Identification and 
transgenic analysis of a murine promoter that targets cholinergic neuron expression. J 
Neurochem, 72, 17-28. 
  
 
  
 
